BRPI0415032A - animais transgênicos que apresentam as pertubações maiores ligadas à doença de alzheimer - Google Patents

animais transgênicos que apresentam as pertubações maiores ligadas à doença de alzheimer

Info

Publication number
BRPI0415032A
BRPI0415032A BRPI0415032-5A BRPI0415032A BRPI0415032A BR PI0415032 A BRPI0415032 A BR PI0415032A BR PI0415032 A BRPI0415032 A BR PI0415032A BR PI0415032 A BRPI0415032 A BR PI0415032A
Authority
BR
Brazil
Prior art keywords
alzheimer
disease
transgenic animals
disorders linked
major disorders
Prior art date
Application number
BRPI0415032-5A
Other languages
English (en)
Inventor
Caty Casas Louzao
Patrick Benoit
Laurent Pradier
Gunter Tremp
Jean-Michel Itier
Veronique Blanchard-Bregeon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0415032A publication Critical patent/BRPI0415032A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ANIMAIS TRANSGêNICOS QUE APRESENTAM AS PERTURBAçõES MAIORES LIGADAS à DOENçA DE ALZHEIMER". A presente invenção se refere a animais transgênicos não humanos que apresentam perturbações maiores ligadas à doença de Alzheimer. Os animais podem ser utilizados para a colocação em evidência de compostos destinados ao tratamento da doença de Alzheimer.
BRPI0415032-5A 2003-10-02 2004-09-27 animais transgênicos que apresentam as pertubações maiores ligadas à doença de alzheimer BRPI0415032A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311578A FR2860391B1 (fr) 2003-10-02 2003-10-02 Animaux transgeniques presentant les troubles majeurs lies a la maladie d'alzheimer
PCT/FR2004/002436 WO2005032244A1 (fr) 2003-10-02 2004-09-27 Animaux transgeniques presentant les troubles majeurs lies a la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
BRPI0415032A true BRPI0415032A (pt) 2006-12-12

Family

ID=34307379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415032-5A BRPI0415032A (pt) 2003-10-02 2004-09-27 animais transgênicos que apresentam as pertubações maiores ligadas à doença de alzheimer

Country Status (22)

Country Link
EP (1) EP1670309B1 (pt)
JP (1) JP4806635B2 (pt)
KR (1) KR101164691B1 (pt)
CN (1) CN1889826A (pt)
AT (1) ATE471661T1 (pt)
AU (1) AU2004277357B2 (pt)
BR (1) BRPI0415032A (pt)
CA (1) CA2540622C (pt)
CY (1) CY1110788T1 (pt)
DE (1) DE602004027823D1 (pt)
DK (1) DK1670309T3 (pt)
ES (1) ES2347961T3 (pt)
FR (1) FR2860391B1 (pt)
IL (1) IL174726A (pt)
MX (2) MXPA06003685A (pt)
NO (1) NO334611B1 (pt)
PL (1) PL1670309T3 (pt)
PT (1) PT1670309E (pt)
RU (1) RU2373707C2 (pt)
SI (1) SI1670309T1 (pt)
WO (1) WO2005032244A1 (pt)
ZA (1) ZA200602670B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963791B1 (fr) * 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris Methode de diagnostic des maladies neurodegeneratives
WO2014007367A1 (ja) * 2012-07-05 2014-01-09 国立大学法人東京大学 同一試料中の２種の物質を検出又は測定する方法
JP6583011B2 (ja) * 2016-01-20 2019-10-02 コニカミノルタ株式会社 酸性水溶液を用いた免疫染色スライドの洗浄方法
CN109776665B (zh) * 2019-02-02 2021-02-05 首都医科大学宣武医院 阿尔茨海默病新突变、其稳转细胞模型及医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509071A (ja) * 1999-09-17 2003-03-11 アバンテイス・フアルマ・エス・アー アミロイド斑およびミトコンドリア機能障害を示すアルツハイマー病の新規の動物モデル
FR2798556B1 (fr) * 1999-09-17 2004-02-27 Aventis Pharma Sa Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
DE60044205D1 (de) * 1999-09-27 2010-05-27 Aventis Pharma Sa Transgenes tier welches ein mehrfach-mutiertes presenilin-1 exprimiert
EP1304922A2 (en) * 2000-07-20 2003-05-02 Cephalon, Inc. Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring

Also Published As

Publication number Publication date
AU2004277357A1 (en) 2005-04-14
FR2860391A1 (fr) 2005-04-08
ZA200602670B (en) 2007-07-25
CA2540622A1 (fr) 2005-04-14
ES2347961T3 (es) 2010-11-26
AU2004277357B2 (en) 2011-11-03
NO20061954L (no) 2006-06-26
IL174726A (en) 2013-05-30
PL1670309T3 (pl) 2010-11-30
DE602004027823D1 (de) 2010-08-05
RU2373707C2 (ru) 2009-11-27
EP1670309A1 (fr) 2006-06-21
EP1670309B1 (fr) 2010-06-23
JP2007507217A (ja) 2007-03-29
MXPA06003670A (es) 2006-06-20
KR20060090988A (ko) 2006-08-17
KR101164691B1 (ko) 2012-07-11
SI1670309T1 (sl) 2010-11-30
ATE471661T1 (de) 2010-07-15
PT1670309E (pt) 2010-09-28
RU2006114692A (ru) 2007-11-10
FR2860391B1 (fr) 2006-01-27
NO334611B1 (no) 2014-04-22
CN1889826A (zh) 2007-01-03
IL174726A0 (en) 2006-08-20
CA2540622C (fr) 2014-01-14
JP4806635B2 (ja) 2011-11-02
CY1110788T1 (el) 2015-06-10
MXPA06003685A (es) 2006-06-20
DK1670309T3 (da) 2010-10-25
WO2005032244A1 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1874282T3 (da) Fremgangsmåder og præparater til behandling af CNS lidelser
BRPI0409634A (pt) ligantes de receptores de canabinóides e utilização destes
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
BR0307998A (pt) Hidroxietilaminas substituìdas
BRPI0410711A (pt) novos compostos
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
HRP20090221B1 (hr) Humanizirano protutijelo
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA200802054A1 (ru) Ингибиторы фермента
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
BR0111140A (pt) Forma polimórfica, composição farmacêutica, métodos para o tratamento de uma doença inflamatória, de uma doença mediada por ciclooxigenase, de dor, e, processo para fabricar um polimorfo de forma v
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
EP1876900A4 (en) PHOSPHOINOSITIDE MODULATION FOR TREATING ALZHEIMER'S DISEASE
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
CY1110788T1 (el) Διαγονιδιακα ζωα τα οποια παρουσιαζουν σημαντικες διαταραχες σχετικες με την νοσο alzheimer
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.